Birch Pollen Allergy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Pages: 36 Published: March 31, 2022 Report Code: GMDGDHC22046IDB

Birch  pollen  allergy  is  a  reaction  which  occurs  soon  after  exposure  to  pollen  of  birch  trees.  Signs  and  symptoms include  skin  reactions,  such  as  hives,  redness  or  swelling,  itching,  or  tingling  in  or  around  the  mouth  and  throat, digestive  problems,  such  as  diarrhea,  stomach  cramps,  nausea  or  vomiting,  tightening  of  the  throat,  shortness  of breath  or  wheezing  and  runny  nose.

The Birch Pollen Allergy – Drugs In Development, research report provides comprehensive  overview on  the  therapeutics  under  development for  Birch  Pollen  Allergy,  complete  with  analysis  by  stage  of  development,  drug  target,  mechanism  of  action  (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics,  its  complete  research  and  development  history  and  latest  news  and  press  releases.  Additionally,  the report provides an overview of key players involved in therapeutic development for Birch Pollen Allergy and features dormant and discontinued projects.

Key Target in the Birch Pollen Allergy Pipeline Drugs Market

The key target in the Birch Pollen Allergy pipeline drugs market is Pollen Allergen Bet v 1.

Key RoA in the Birch Pollen Allergy Pipeline Drugs Market

The key routes of administration in the Birch Pollen Allergy pipeline drugs market are intravenous, sublingual, and subcutaneous.

Birch Pollen Allergy Pipeline Drugs Market, by RoA

Birch Pollen Allergy Pipeline Drugs Market, by RoA

To get more insights on key RoA, download a free sample report

Key Molecule Types in the Birch Pollen Allergy Pipeline Drugs Market

The key molecule types in the Birch Pollen Allergy pipeline drugs market are Allergenics (Allergen), Monoclonal Antibody, Subunit Vaccine and Vaccine.

Birch Pollen Allergy Pipeline Drugs Market, by Molecule Type

Birch Pollen Allergy Pipeline Drugs Market, by Molecule Type

To get more updates on the top molecule types, download a free sample report

Major Companies in the Birch Pollen Allergy Pipeline Drugs Market

The major companies in the Birch Pollen Allergy pipeline drugs market are Regeneron Pharmaceuticals Inc, Allergy Therapeutics Plc, Desentum Oy, HAL Allergy BV, Roxall Medizin GmbH, Worg Pharmaceuticals, and S-TARget therapeutics GmbH.

Birch Pollen Allergy Pipeline Drugs Market, by Companies

 

Birch Pollen Allergy Pipeline Drugs Market, by Companies

For more company insights, download a free sample report

Birch Pollen Allergy Pipeline Drugs Market Overview

Key target Pollen Allergen Bet v 1
Key molecules Allergenics (Allergen), Monoclonal Antibody, Subunit Vaccine and Vaccine
Key routes Intravenous, Sublingual, and Subcutaneous
Key companies Regeneron Pharmaceuticals Inc, Allergy Therapeutics Plc, Desentum Oy, HAL Allergy BV, Roxall Medizin GmbH, Worg Pharmaceuticals, and S-TARget therapeutics GmbH

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Birch Pollen Allergy
  • The pipeline guide reviews pipeline therapeutics for Birch Pollen Allergy by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Birch Pollen Allergy therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Birch Pollen Allergy therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews the latest news related to pipeline therapeutics for Birch Pollen Allergy

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with a potentially strong product portfolio and create effective counter-strategies to gain a competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Birch Pollen Allergy
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Birch Pollen Allergy pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.

Key Players

  • Allergy Therapeutics Plc

    Desentum Oy

    HAL Allergy BV

    Regeneron Pharmaceuticals Inc

    Roxall Medizin GmbH

    S-TARget therapeutics GmbH

    Worg Pharmaceuticals Hangzhou Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Birch Pollen Allergy – Overview

Birch Pollen Allergy – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Birch Pollen Allergy – Therapeutics Assessment

Assessment by Target

Assessment by Route of Administration

Assessment by Molecule Type

Birch Pollen Allergy – Companies Involved in Therapeutics Development

Allergy Therapeutics Plc

Desentum Oy

HAL Allergy BV

Regeneron Pharmaceuticals Inc

Roxall Medizin GmbH

S-TARget therapeutics GmbH

Worg Pharmaceuticals Hangzhou Co Ltd

Birch Pollen Allergy – Drug Profiles

Allergen for Birch Pollen Allergy – Drug Profile

Product Description

Mechanism Of Action

birch pollen allergen extract – Drug Profile

Product Description

Mechanism Of Action

History of Events

DM-101 – Drug Profile

Product Description

Mechanism Of Action

History of Events

Pollinex Quattro Birch – Drug Profile

Product Description

Mechanism Of Action

History of Events

REGN5713-5714-5715 – Drug Profile

Product Description

Mechanism Of Action

History of Events

SG-300 – Drug Profile

Product Description

Mechanism Of Action

WP-1074 – Drug Profile

Product Description

Mechanism Of Action

Birch Pollen Allergy – Dormant Projects

Birch Pollen Allergy – Discontinued Products

Birch Pollen Allergy – Product Development Milestones

Featured News & Press Releases

Oct 25, 2021: Desentum reports positive findings for the First-in-Human clinical study of lead product candidate in birch pollen allergic adults

Nov 01, 2019: Desentum will run a clinical trial on its allergy vaccine this winter supported by 4 M€ of new investments

Mar 18, 2019: Allergy Therapeutics’ birch pollen product fails to meet primary endpoint

Aug 14, 2018: HAL Allergy first company to achieve marketing authorisations in line with Therapieallergene-Verordnung (TAV) in Germany

Jun 14, 2017: Desentum has two presentations in EAACI 2017

May 10, 2017: Desentum is preparing to start clinical trials with birch pollen allergy vaccine

Mar 16, 2017: Allergy Therapeutics Announces First Patient Recruited in Pivotal Phase III Birch Immunotherapy B301 Study

May 17, 2016: HAL Allergy has successfully completed its Phase III short-term efficacy trial with its sublingual allergen immunotherapy (SLIT) liquid product for the treatment of birch pollen allergy

May 09, 2016: Allergy Therapeutics Announces Positive Top-Line Results From the PQBirch204 Phase II Study for Birch-Induced Seasonal Allergic Rhinitis

Sep 01, 2015: First patient recruited in Pollinex Quattro Birch dose ranging study in Germany and Austria

Mar 10, 2015: Positive Outcome of the PURETHAL Birch RUSH Study Results in an Approved, Accelerated up-dosing Regimen

May 12, 2013: Desentum: EARTO innovation prize to VTT

Mar 09, 2006: Stallergenes Reports Positive Study Results with Biomay´s Bet v 1

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Birch Pollen Allergy, 2022

Number of Products under Development by Companies, 2022

Products under Development by Companies, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Birch Pollen Allergy – Pipeline by Allergy Therapeutics Plc, 2022

Birch Pollen Allergy – Pipeline by Desentum Oy, 2022

Birch Pollen Allergy – Pipeline by HAL Allergy BV, 2022

Birch Pollen Allergy – Pipeline by Regeneron Pharmaceuticals Inc, 2022

Birch Pollen Allergy – Pipeline by Roxall Medizin GmbH, 2022

Birch Pollen Allergy – Pipeline by S-TARget therapeutics GmbH, 2022

Birch Pollen Allergy – Pipeline by Worg Pharmaceuticals Hangzhou Co Ltd, 2022

Birch Pollen Allergy – Dormant Projects, 2022

Birch Pollen Allergy – Discontinued Products, 2022

List of Figures

List of Figures

Number of Products under Development for Birch Pollen Allergy, 2022

Number of Products under Development by Companies, 2022

Number of Products by Stage and Targets, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

Frequently Asked Questions

$2000

Can be used by individual purchaser only

$6000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.